These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 27713306)

  • 41. What is 'best practice' in health care? State of the art and perspectives in improving the effectiveness and efficiency of the European health care systems.
    Perleth M; Jakubowski E; Busse R
    Health Policy; 2001 Jun; 56(3):235-50. PubMed ID: 11399348
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antibiotic prophylaxis for haematogenous bacterial arthritis in patients with joint disease: a cost effectiveness analysis.
    Krijnen P; Kaandorp CJ; Steyerberg EW; van Schaardenburg D; Moens HJ; Habbema JD
    Ann Rheum Dis; 2001 Apr; 60(4):359-66. PubMed ID: 11247866
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Are pharmaceuticals cost-effective? A review of the evidence.
    Neumann PJ; Sandberg EA; Bell CM; Stone PW; Chapman RH
    Health Aff (Millwood); 2000; 19(2):92-109. PubMed ID: 10718025
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Questionable history of immediate-type hypersensitivity to penicillin in Staphylococcal endocarditis: treatment based on skin-test results vers-us empirical alternative treatment--A decision analysis.
    Dodek P; Phillips P
    Clin Infect Dis; 1999 Nov; 29(5):1251-6. PubMed ID: 10524971
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness of transesophageal echocardiography to determine the duration of therapy for intravascular catheter-associated Staphylococcus aureus bacteremia.
    Rosen AB; Fowler VG; Corey GR; Downs SM; Biddle AK; Li J; Jollis JG
    Ann Intern Med; 1999 May; 130(10):810-20. PubMed ID: 10366370
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group.
    Grossman R; Mukherjee J; Vaughan D; Eastwood C; Cook R; LaForge J; Lampron N
    Chest; 1998 Jan; 113(1):131-41. PubMed ID: 9440580
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Test-treatment strategies for patients suspected of having Lyme disease: a cost-effectiveness analysis.
    Nichol G; Dennis DT; Steere AC; Lightfoot R; Wells G; Shea B; Tugwell P
    Ann Intern Med; 1998 Jan; 128(1):37-48. PubMed ID: 9424980
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of suspected urinary tract infection in ambulatory women: a cost-utility analysis of office-based strategies.
    Barry HC; Ebell MH; Hickner J
    J Fam Pract; 1997 Jan; 44(1):49-60. PubMed ID: 9010371
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A cost-utility analysis of second-line antibiotics in the treatment of acute otitis media in children.
    Oh PI; Maerov P; Pritchard D; Knowles SR; Einarson TR; Shear NH
    Clin Ther; 1996; 18(1):160-82. PubMed ID: 8851461
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recommendations of the Panel on Cost-effectiveness in Health and Medicine.
    Weinstein MC; Siegel JE; Gold MR; Kamlet MS; Russell LB
    JAMA; 1996 Oct; 276(15):1253-8. PubMed ID: 8849754
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis.
    Briggs A; Sculpher M; Buxton M
    Health Econ; 1994; 3(2):95-104. PubMed ID: 8044216
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Foot infections in diabetic patients. Decision and cost-effectiveness analyses.
    Eckman MH; Greenfield S; Mackey WC; Wong JB; Kaplan S; Sullivan L; Dukes K; Pauker SG
    JAMA; 1995 Mar; 273(9):712-20. PubMed ID: 7853629
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-effectiveness of antibiotic prophylaxis for dental procedures in patients with artificial joints.
    Tsevat J; Durand-Zaleski I; Pauker SG
    Am J Public Health; 1989 Jun; 79(6):739-43. PubMed ID: 2499200
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimal management strategies for HIV-infected patients who present with cough or dyspnea: a cost-effective analysis.
    Freedberg KA; Tosteson AN; Cotton DJ; Goldman L
    J Gen Intern Med; 1992; 7(3):261-72. PubMed ID: 1351940
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Health Economics of Antibiotics.
    Simoens S
    Pharmaceuticals (Basel); 2010 Apr; 3(5):1348-1359. PubMed ID: 27713306
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
    Tappenden P; Jones R; Paisley S; Carroll C
    Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure.
    Croom KF; Plosker GL
    Pharmacoeconomics; 2005; 23(10):1057-72. PubMed ID: 16235978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.